1. Home
  2. NUR vs ENVB Comparison

NUR vs ENVB Comparison

Compare NUR & ENVB Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Nuran Wireless Inc. Common Shares

NUR

Nuran Wireless Inc. Common Shares

N/A

Current Price

$0.40

Market Cap

7.8M

Sector

N/A

ML Signal

N/A

ENVB

Enveric Biosciences Inc.

N/A

Current Price

$1.52

Market Cap

6.4M

Sector

Health Care

ML Signal

N/A

Company Overview

Basic Information
Metric
NUR
ENVB
Founded
N/A
1994
Country
Canada
United States
Employees
N/A
N/A
Industry
Biotechnology: Pharmaceutical Preparations
Sector
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
7.8M
6.4M
IPO Year
2016
2000

Fundamental Metrics

Financial Performance
Metric
NUR
ENVB
Price
$0.40
$1.52
Analyst Decision
Analyst Count
0
0
Target Price
N/A
N/A
AVG Volume (30 Days)
★ 446.6K
28.3K
Earning Date
08-28-2026
11-24-2026
Dividend Yield
N/A
N/A
EPS Growth
★ N/A
N/A
EPS
★ N/A
N/A
Revenue
N/A
★ $39,914,675.00
Revenue This Year
N/A
N/A
Revenue Next Year
N/A
N/A
P/E Ratio
N/A
★ N/A
Revenue Growth
★ N/A
N/A
52 Week Low
$0.36
$1.17
52 Week High
$7.72
$795.00

Technical Indicators

Market Signals
Indicator
NUR
ENVB
Relative Strength Index (RSI) 25.39 56.40
Support Level $0.36 $1.35
Resistance Level $0.83 $1.55
Average True Range (ATR) 0.09 0.10
MACD 0.00 0.01
Stochastic Oscillator 8.97 73.20

Price Performance

Historical Comparison
NUR
ENVB

About NUR Nuran Wireless Inc. Common Shares

Nuran Wireless Inc is engaged in the Network as a Service (NAAS) business. The group operates in the research, development, manufacturing, marketing, and operation of digital electronic circuits and wireless telecommunication products and offers services in the mobile telephony industry. It also provides products and services that help mobile network operators profitably serve off-grid markets that are currently not served. It has two reportable segments: NaaS and Direct Sales. The majority of the revenue is derived from Africa.

About ENVB Enveric Biosciences Inc.

Enveric Biosciences Inc is a biotechnology company dedicated to the development of novel neuroplastogenic small-molecule therapeutics for the treatment of depression, anxiety, addiction, and other psychiatric disorders. The company's program, EB-003, is a first-in-class approach to the treatment of difficult-to-address mental health disorders designed to promote neuroplasticity without inducing hallucinations in the patient. The company is also developing EB-002, formerly EB-373, a next-generation synthetic prodrug of the active metabolite, psilocin, which is being studied as a treatment for psychiatric disorders.

Share on Social Networks: